Kite Pharma

Kite Pharma is a global leader in cell therapy, operating as an independent subsidiary of Gilead Sciences. The company has commercialized two autologous CAR T-cell therapies, Yescarta and Tecartus, for various B-cell malignancies, establishing a significant presence in the immuno-oncology market. With a deep pipeline exploring next-generation cell therapies and manufacturing innovations, Kite aims to extend its curative potential to more cancer types. Its business model is fully integrated, encompassing R&D, manufacturing, and commercialization of its proprietary therapeutics.

Autologous chimeric antigen receptor (CAR) T-cell therapy platform, involving the engineering of a patient's own T cells to target specific cancer antigens.

Kite competes in a dynamic CAR-T market with major players like Bristol Myers Squibb (Breyanzi, Abecma), Novartis (Kymriah), and Johnson & Johnson/Legend Biotech (Carvykti). Competition is based on efficacy, safety profile, manufacturing speed, and commercial reach. The landscape also includes emerging modalities like allogeneic CAR-T and bi-specific T-cell engagers.